Live Oak Health Sciences Fund
Live Oak Health Sciences Fund reported 27 holdings worth US$56.1M as of Jul 31, 2026 (Form N-PORT)
As of Jul 31, 2026 · Filed Sep 29, 2026
Live Oak Health Sciences Fund reported 27 holdings worth US$56.1M as of Jul 31, 2026. Largest: Cardinal Health, Inc., Jazz Pharmaceuticals Plc and United Therapeutics Corporation. Filed Sep 29, 2026 (Form N-PORT).
- Holdings
- 27
- Value as reported
- US$56.1M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cardinal Health, Inc. | 14,297 | US$3.29M | 5.9% |
| Jazz Pharmaceuticals Plc | 12,812 | US$3.24M | 5.8% |
| United Therapeutics Corporation | 5,543 | US$2.87M | 5.1% |
| Exelixis, Inc. | 52,445 | US$2.78M | 5.0% |
| Amgen Inc. | 7,077 | US$2.73M | 4.9% |
| Lantheus Holdings, Inc. | 26,355 | US$2.63M | 4.7% |
| Novartis Ag | 16,819 | US$2.62M | 4.7% |
| Mckesson Corporation | 2,973 | US$2.55M | 4.5% |
| Cencora, Inc. | 8,034 | US$2.5M | 4.5% |
| Regeneron Pharmaceuticals, Inc. | 3,260 | US$2.49M | 4.4% |
| Bristol-myers Squibb Company | 34,526 | US$2.25M | 4.0% |
| National Healthcare Corporation | 9,612 | US$2.17M | 3.9% |
| Johnson & Johnson | 8,261 | US$2.12M | 3.8% |
| Medpace Holdings, Inc. | 3,593 | US$2.07M | 3.7% |
| Gilead Sciences, Inc. | 15,105 | US$1.97M | 3.5% |
| The Cigna Group | 6,955 | US$1.94M | 3.5% |
| Incyte Corporation | 15,511 | US$1.85M | 3.3% |
| Vertex Pharmaceuticals Incorporated | 3,831 | US$1.83M | 3.3% |
| Merck & Company, Inc. | 13,629 | US$1.77M | 3.2% |
| Medtronic Plc. | 19,761 | US$1.69M | 3.0% |
| Intuitive Surgical, Inc. | 4,755 | US$1.68M | 3.0% |
| Novo Nordisk A/s Class B | 30,347 | US$1.41M | 2.5% |
| Labcorp Holdings Inc. | 4,153 | US$1.28M | 2.3% |
| Eli Lilly And Company | 970 | US$1.11M | 2.0% |
| Stryker Corporation | 3,396 | US$1.11M | 2.0% |
| Elevance Health, Inc. | 1,621 | US$609K | 1.1% |
| The Ensign Group, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related